Skip to content
OpenCapital
Get started

Esperion Therapeutics ESPR Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value at other companies

Organon logo
OrganonOGN
——

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K—
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%—

Returns & leverage

See full
Return on equity-260.8%—
Debt / equity0.8×—
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
Esperion Therapeutics (ESPR) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value of $4.75M in Q1 2026.
How has Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value changed year-over-year?
Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value increased by 39500.0% year-over-year, from $12K to $4.75M.
What is the long-term trend for Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
Over 2 years (2020 to 2025), Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value has grown at a -34.1% compound annual growth rate (CAGR), from $18.42M to $8M.